search
Back to results

Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder

Primary Purpose

Urinary Bladder, Overactive

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MagPro R30
Sponsored by
EMKinetics, Inc
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Bladder, Overactive focused on measuring Overactive Bladder, Overactive Urinary Bladder, Bladder, Overactive, Overactive Detrusor, Detrusor, Overactive, Overactive Detrusor Function, Detrusor Function, Overactive

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient is > 18 years old.
  • The patient has ≥ 6 month history of documented overactive bladder.
  • The patient has failed other conventional therapy (i.e.- Kegel exercises, biofeedback methodology, etc.).
  • The patient is free of mechanical urethral obstruction as documented by cystoscopy or pressure flow criteria.
  • The patient demonstrates an understanding of neuromodulation therapy, its benefits, and its potential risks.
  • The patient is willing and able to keep accurate records of their voiding on the provided voiding diaries.
  • The patient is willing and able to comply with the Study Protocol.
  • The patient agrees to and is capable of answering a quality of life questionnaire.
  • The patient has normal functioning of the upper urinary tract.
  • The patient has an intact peripheral neurosensory system.
  • If the patient is/was on pharmacologic treatment for urgency/frequency syndrome, a 10-day washout period prior to treatment must be completed.
  • The patient has sufficient outlet resistance at the urinary sphincter (i.e.- the patient does not have intrinsic sphincter deficiency).

Exclusion Criteria:

  • The patient is pregnant or intends to become pregnant during the course of the study. (Patients becoming pregnant during the course of the study will immediately be terminated from the study.) Warning: The effects of neuromodulation on a developing fetus are unknown
  • The patient has an active urinary tract infection.
  • The patient has abnormal cystoscopy, which is concerning for or indicative of malignancy.
  • The patient has a urinary fistula.
  • The patient has a bladder stone.
  • The patient has had ankle injury or surgery which results inability to stimulate the tibial nerve or discomfort in using the foot cradle
  • The patient has metal implant from surgery or a metallic foreign body in either leg below (distal to) the knee.
  • The patient has cochlear implants.
  • The patient has a hyperreflexic neurogenic bladder or urodynamically proven instability secondary to a known neurourologic cause (i.e.- stroke, Parkinson's, Multiple Sclerosis).
  • The patient has had four or more urinary tract infections in the past year.
  • The patient has a chronic disease or diminished mental capacity that, in the Principal Investigator's judgement, would impair their ability to successfully understand and comply with the protocol.
  • The patient has a history of gross hematuria or glycosuria within the last year.
  • The patient has chronic constipation (less than two (2) bowel movements per week).
  • The patient has significant pathology that would compromise sphincter competency.
  • The patient has uncontrolled diabetes.
  • The patient has diagnosed peripheral neuropathy such as diabetes with peripheral nerve involvement.
  • The patient has concomitant medical conditions that would limit the success of the procedure or confound study results, including but not limited to patients with nerve damage, pacemakers or implantable defibrillators.
  • The patient is unable or unwilling to sign informed consent.
  • The patient is on pharmacologic treatment that could affect bladder function.
  • The patient has known moderate to severe ureteral reflux or hydronephrosis.
  • The patient has severe urethral stricture(s).

Sites / Locations

  • UCSF Urology Faculty Practice

Outcomes

Primary Outcome Measures

Improved urinary frequency and urgency after 12 weeks of treatment.

Secondary Outcome Measures

To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls
To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent
To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc

Full Information

First Posted
December 8, 2008
Last Updated
June 6, 2011
Sponsor
EMKinetics, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT00805779
Brief Title
Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder
Official Title
Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Terminated
Why Stopped
Major protocol changes needeed
Study Start Date
December 2008 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
April 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
EMKinetics, Inc

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To assess the initial safety and clinical feasibility of neuromodulation therapy in treating patients with documented overactive bladder. The specific aim is improved urinary frequency and urgency after 12 weeks of treatment
Detailed Description
Twenty to Forty patients with documented overactive bladder will receive 30 minutes of treatment one day a week for 12 weeks. Treatment will consist of stimulating the posterior tibial nerve in the area of the ankle with a pulsed electromagnetic field. Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil, and a surface electrode placed over the afferent pathway of the sacral nerve. The specific aim is improved urinary frequency and urgency after 12 weeks of treatment. Secondary goals. To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls. To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Bladder, Overactive
Keywords
Overactive Bladder, Overactive Urinary Bladder, Bladder, Overactive, Overactive Detrusor, Detrusor, Overactive, Overactive Detrusor Function, Detrusor Function, Overactive

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
MagPro R30
Intervention Description
Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
Primary Outcome Measure Information:
Title
Improved urinary frequency and urgency after 12 weeks of treatment.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
To estimate the extent to which the device will decrease the number of episodes of involuntary urine loss due to frequency/urgency in comparison to historical controls
Time Frame
12 weeks
Title
To evaluate the potential of the device for improving patient quality of life as measured by a clinically validated scale, such as the Incontinence Quality of Life Instrument (I-QOL) or equivalent
Time Frame
12 weeks
Title
To periodically employ a micturition diary to record variables such as day/night urgency/frequency episodes, number of voids per day, severity of leaks, number of absorbent products used per day, etc
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient is > 18 years old. The patient has ≥ 6 month history of documented overactive bladder. The patient has failed other conventional therapy (i.e.- Kegel exercises, biofeedback methodology, etc.). The patient is free of mechanical urethral obstruction as documented by cystoscopy or pressure flow criteria. The patient demonstrates an understanding of neuromodulation therapy, its benefits, and its potential risks. The patient is willing and able to keep accurate records of their voiding on the provided voiding diaries. The patient is willing and able to comply with the Study Protocol. The patient agrees to and is capable of answering a quality of life questionnaire. The patient has normal functioning of the upper urinary tract. The patient has an intact peripheral neurosensory system. If the patient is/was on pharmacologic treatment for urgency/frequency syndrome, a 10-day washout period prior to treatment must be completed. The patient has sufficient outlet resistance at the urinary sphincter (i.e.- the patient does not have intrinsic sphincter deficiency). Exclusion Criteria: The patient is pregnant or intends to become pregnant during the course of the study. (Patients becoming pregnant during the course of the study will immediately be terminated from the study.) Warning: The effects of neuromodulation on a developing fetus are unknown The patient has an active urinary tract infection. The patient has abnormal cystoscopy, which is concerning for or indicative of malignancy. The patient has a urinary fistula. The patient has a bladder stone. The patient has had ankle injury or surgery which results inability to stimulate the tibial nerve or discomfort in using the foot cradle The patient has metal implant from surgery or a metallic foreign body in either leg below (distal to) the knee. The patient has cochlear implants. The patient has a hyperreflexic neurogenic bladder or urodynamically proven instability secondary to a known neurourologic cause (i.e.- stroke, Parkinson's, Multiple Sclerosis). The patient has had four or more urinary tract infections in the past year. The patient has a chronic disease or diminished mental capacity that, in the Principal Investigator's judgement, would impair their ability to successfully understand and comply with the protocol. The patient has a history of gross hematuria or glycosuria within the last year. The patient has chronic constipation (less than two (2) bowel movements per week). The patient has significant pathology that would compromise sphincter competency. The patient has uncontrolled diabetes. The patient has diagnosed peripheral neuropathy such as diabetes with peripheral nerve involvement. The patient has concomitant medical conditions that would limit the success of the procedure or confound study results, including but not limited to patients with nerve damage, pacemakers or implantable defibrillators. The patient is unable or unwilling to sign informed consent. The patient is on pharmacologic treatment that could affect bladder function. The patient has known moderate to severe ureteral reflux or hydronephrosis. The patient has severe urethral stricture(s).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Donna Y Deng, MD
Organizational Affiliation
UCSF Department of Urology
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCSF Urology Faculty Practice
City
San Francisco
State/Province
California
ZIP/Postal Code
94122
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder

We'll reach out to this number within 24 hrs